Nalmefene

Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist. It functions as a antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence. Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose. Nalmefene injection is used to manage known or suspected opioid overdose. It is used for complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. The nasal spray formulation of nalmefene was approved by the FDA in May 2023. It is grouped under the following drug class(es): Opioid dependence agents. Its therapeutic use is listed as alcohol dependence agents. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Nalmetrene and Nalmefeno. Its PubChem CID is 5284594.

CAS No 55096-26-9
Molecular Formula C21H25NO3
Molecular Weight 339.4 g/mol
Synonyms (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol

Frequently Asked Questions